GenSight

By Laverne J. Tiffany 4 years ago

PARIS–(Business WIRE)–Jan 18, 2021– GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME suitable), a biopharma